Oral Metronomic Capecitabine Combined With Pyrotinib in ADC-treated HER2-positive Metastatic Breast Cancer

This is a prospective, open-label, multi-cohort, phase II study to evaluate the efficacy and safety of Oral metronomic capecitabine combined with pyrotinib in patients with HER2-positive advanced breast cancer who had received prior anti-HER2 ADC drugs (including T-DXd, SHR-A1811, T-DM1, etc.) before treatment.

NCT Number	NCT07019337
Lead Sponsor	Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Conditions	HER2-positive Breast Cancer, Metastatic Breast Cancer
Enrollment	100 participants
Start Date	2025-06-30
Primary Completion	2028-07-31 (estimated)
Study Completion	2030-12-31 (estimated)
Updated on ClinicalTrials.gov	2025-06-13